SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO)

Historical Holders from Q3 2018 to Q3 2025

Symbol
STRO on Nasdaq
CUSIP
869367102
Type / Class
Equity / Common Stock, par value $0.001 per share
Shares outstanding
84.7M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
53.4M
Holdings value
$46.4M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
85
Number of buys
29
Number of sells
-54
Average Value change %
+0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Affinity Asset Advisors, LLC 7.77% $5.72M 6.58M Affinity Healthcare Fund, LP Oct 16, 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% $4.63M 6.49M Suvretta Capital Management, LLC Jun 30, 2025
MILLENNIUM MANAGEMENT LLC 5.6% $4.43M 4.72M Millennium Management LLC Jun 27, 2025
VANGUARD GROUP INC 4.87% $2.94M 4.12M The Vanguard Group Jun 30, 2025
BlackRock, Inc. 2.5% -68.6% $1.49M -$2.89M 2.09M -65.9% BlackRock, Inc. Jun 30, 2025

Institutional Holders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 53.4M $46.4M -$1.65M $0.87 85
2025 Q2 55.6M $39.7M -$3.65M $0.71 100
2025 Q1 61.5M $40M -$10.8M $0.65 113
2024 Q4 63.9M $118M -$7.31M $1.84 122
2024 Q3 62.5M $216M -$1.66M $3.46 130
2024 Q2 63.2M $185M +$25.1M $2.93 119
2024 Q1 53.4M $302M +$2.09M $5.65 116
2023 Q4 55.6M $239M -$219K $4.29 113
2023 Q3 56M $194M +$5.62M $3.47 108
2023 Q2 54.1M $252M +$2.18M $4.65 119
2023 Q1 53.7M $248M +$10.5M $4.62 114
2022 Q4 50M $404M +$6.3M $8.08 115
2022 Q3 50.4M $280M +$23.5M $5.55 110
2022 Q2 46.2M $241M +$15.7M $5.21 111
2022 Q1 41.6M $342M -$38.5M $8.22 111
2021 Q4 39.7M $590M -$4.36M $14.88 115
2021 Q3 39.8M $752M -$26.4M $18.89 119
2021 Q2 41.2M $767M -$71.9M $18.59 121
2021 Q1 44.2M $1.01B +$115M $22.76 136
2020 Q4 39.4M $855M +$185M $21.71 133
2020 Q3 31.2M $313M +$67.5M $10.05 87
2020 Q2 24M $186M +$97.6M $7.76 76
2020 Q1 11.9M $116M +$7.87M $10.20 60
2019 Q4 11.6M $128M +$7.09M $11.00 64
2019 Q3 11.1M $91.6M -$8.3M $9.09 59
2019 Q2 11.8M $123M +$6.67M $11.38 58
2019 Q1 11.2M $116M +$4.73M $11.39 49
2018 Q4 9.71M $87.2M -$10.6M $9.02 41
2018 Q3 9.09M $136M +$129M $15.00 32